{
    "clinical_study": {
        "@rank": "141069", 
        "arm_group": {
            "arm_group_label": "Abiraterone acetate plus prednisone"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of abiraterone acetate in\n      male Filipino patients with advanced metastatic castration resistant prostate cancer (CRPC)\n      who have received prior chemotherapy containing a taxane."
        }, 
        "brief_title": "Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Prostatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label (identity of assigned study drug will be known), observational study\n      to evaluate the safety and efficacy of abiraterone acetate in male Filipino patients with\n      advanced metastatic CRPC who have received prior chemotherapy containing a taxane.\n      Approximately 50 patients will be enrolled. Abiraterone acetate will be administered\n      according to the approved product insert with a low-dose glucocorticoid (prednisone or\n      prednisolone). Patient assessments will be based on the accepted clinical practice in the\n      Philippines. Patients will be monitored for 40 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed adenocarcinoma of the prostate without\n             neuroendocrine differentiation or small cell histology\n\n          -  Received at least 1 but not more than 2 cytotoxic chemotherapy regimens for\n             metastatic castration resistant prostate cancer (CRPC) (at least 1 regimen must have\n             contained a taxane such as docetaxel; if a chemotherapy regimen containing a taxane\n             is used more than once, this will be considered as 1 regimen)\n\n          -  Agrees to protocol-defined use of effective contraception\n\n          -  Laboratory values within protocol -defined parameters\n\n        Exclusion Criteria:\n\n          -  Serious or uncontrolled co-existent non-malignant disease, including active and\n             uncontrolled infection\n\n          -  Abnormal liver function\n\n          -  Uncontrolled hypertension (systolic blood pressure >=160 mmHg or diastolic blood\n             pressure >=95 mmHg)\n\n          -  Active or symptomatic viral hepatitis or chronic liver disease\n\n          -  History of pituitary or adrenal dysfunction\n\n          -  Clinically significant heart disease as evidenced by myocardial infarction, or\n             arterial thrombotic events in the past 6 months, severe or unstable angina, or New\n             York Heart Association (NYHA) Class III or IV heart disease or left ventricular\n             ejection fraction of <50% at baseline\n\n          -  Known brain metastasis\n\n          -  History of gastrointestinal disorders (medical disorders or extensive surgery) that\n             may interfere with the absorption of the study drug\n\n          -  Any acute toxicities due to prior chemotherapy or radiotherapy that have not resolved\n             to a NCI-CTCAE (Version 4.0) Grade of <=1\n\n          -  Prior systemic treatment with an azole drug (eg, fluconazole, itraconazole,\n             ketoconazole) within 4 weeks of Cycle 1, Day 1\n\n          -  Condition or situation which, in the investigator's opinion, may put the patient at\n             significant risk, may confound the study results, or may interfere significantly with\n             patient's participation in the study\n\n          -  Participation in an investigational drug trial within 30 days prior to selection\n\n          -  Known hypersensitivity to abiraterone acetate, or to any of the components in the\n             formulation"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Male Filipino patients with advanced metastatic castration resistant prostate cancer"
            }
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01692483", 
            "org_study_id": "CR100856", 
            "secondary_id": "212082PCR4003"
        }, 
        "intervention": [
            {
                "arm_group_label": "Abiraterone acetate plus prednisone", 
                "description": "Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily", 
                "intervention_name": "Abiraterone acetate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Abiraterone acetate plus prednisone", 
                "description": "Prednisone or prednisolone 5 mg tablet taken orally twice daily", 
                "intervention_name": "Prednisone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Prednisone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Prostate neoplasms", 
            "Prostate cancer", 
            "Castration resistant prostate cancer", 
            "Hormone refractory prostate cancer", 
            "Abiraterone acetate", 
            "Taxane"
        ], 
        "lastchanged_date": "June 24, 2013", 
        "number_of_groups": "1", 
        "official_title": "Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Metastatic Advanced Prostate Cancer", 
        "overall_official": {
            "affiliation": "Janssen Pharmaceutica, Philippines", 
            "last_name": "is  Janssen Pharmaceutica, Philippines Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Philippines: Bureau of Food and Drugs", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants affected by an adverse event", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 30 days after the last dose of study medication"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01692483"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of patients with disease progression", 
            "safety_issue": "No", 
            "time_frame": "Baseline up to Week 40"
        }, 
        "source": "Janssen Pharmaceutica", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Pharmaceutica", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2013", 
        "why_stopped": "Sponsor determined study is not required according to PFDA Circular 2013-004"
    }
}